We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression

This study has been terminated.
(Enrollment difficulties)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01794455
First Posted: February 18, 2013
Last Update Posted: October 20, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Warren Taylor, Vanderbilt University
February 12, 2013
February 18, 2013
July 18, 2016
October 20, 2016
October 20, 2016
May 2013
March 2015   (Final data collection date for primary outcome measure)
  • MRI Arterial Spin Labeling [ Time Frame: Change in perfusion from baseline to week 8 ]
    MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 1 sertraline arm.
  • Montgomery Asberg Depression Rating Scale (MADRS) [ Time Frame: Week 8 ]
    MADRS is a measure of depression severity. This outcome applies to the sertraline Phase 1 arm.
Same as current
Complete list of historical versions of study NCT01794455 on ClinicalTrials.gov Archive Site
  • Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16) [ Time Frame: Week 8 ]
    Self-report measure of depression severity. This applies to the sertraline Phase 1 arm.
  • Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16) [ Time Frame: Week 20 ]
    Self-report measure of depression severity (range 0 - 27, higher scores indicate more severe depressive symptoms). This applies to the candesartan Phase 2 arm.
  • Montgomery-Asberg Depression Rating Scale [ Time Frame: Week 20 ]
    MADRS is a measure of depression severity (range 0 - 60, higher scores indicate more severe depressive symptoms). This outcome applies to the candesartan Phase 2 arm.
  • MRI Arterial Spin Labeling [ Time Frame: Change from week 8 to week 20 ]
    MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 2 candesartan arm.
  • Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16) [ Time Frame: Week 8 ]
    Self-report measure of depression severity. This applies to the sertraline Phase 1 arm.
  • Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16) [ Time Frame: Week 20 ]
    Self-report measure of depression severity. This applies to the candesartan Phase 2 arm.
  • Montgomery-Asberg Depression Rating Scale [ Time Frame: Week 20 ]
    MADRS is a measure of depression severity. This outcome applies to the candesartan Phase 2 arm.
  • MRI Arterial Spin Labeling [ Time Frame: Change from week 8 to week 20 ]
    MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 2 candesartan arm.
Not Provided
Not Provided
 
Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression
Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression
This pilot proposal will test the hypothesis that altered cerebral vessel reactivity and cerebral hypoperfusion (decreased blood flow to the brain) is a core mechanism underlying the relationship between vascular disease and depression in older adults. The long-term objective of this line of research is to: A) determine the relationship between vascular reactivity, cerebral hypoperfusion and the persistence of late-life depression and B) determine if improving cerebral perfusion with angiotensin receptor blockers (ARBs) improves depression outcomes.

This study will examine how magnetic resonance imaging (MRI) measures of cerebral perfusion relate to antidepressant response. There are two phases to the study. In the first phase, we will examine how cerebral perfusion is related to response to sertraline, a commonly used antidepressant. In the second phase, we will examine individuals who do not respond to sertraline or other selective serotonin reuptake inhibitors (SSRI). We will examine if candesartan, an ARB, improves depression and if it does so by improving cerebral perfusion.

After providing informed consent, participants will undergo medical and psychiatric screening. Participants determined to be eligible at the screen will proceed to a baseline evaluation, which will include brief cognitive neuropsychological testing and MRI. Participants will then begin open-label sertraline for eight weeks (baseline to week 8). Dosing will begin at 50mg daily and, based on response and tolerability, can increase up to the FDA approved maximum dose of 200mg daily.

After the eight weeks, participants will be re-evaluated and complete another MRI. Those who respond to sertraline and experience remission of their depression will end their study participation. Those who do not experience remission will continue to the phase 2 open-label candesartan arm.

The candesartan arm will last for 12 weeks (week 8 to week 20). Dosing will begin at 4mg daily and can increase to a maximum dose of 32mg, based on tolerability and response. Participants will be monitored closely, and other antihypertensive medications adjusted to avoid low blood pressure. At the end of the 12-week trial, participants will again complete MRI and neuropsychological testing. Their study participation will then end.

Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
  • Depression
  • Hypertension
  • Drug: Sertraline
    50mg - 200mg daily
    Other Name: Zoloft
  • Drug: Candesartan
    4mg - 32mg daily
    Other Name: Atacand
  • Experimental: Phase 1: Sertraline
    Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
    Intervention: Drug: Sertraline
  • Experimental: Phase 2: Candesartan
    For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
    Intervention: Drug: Candesartan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
1
March 2015
March 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 60 years or older
  2. Diagnosis of Major Depressive Disorder, single or recurrent episode, without psychotic features by Diagnostic and Statistical Manual IV Text Revision (DSMIV-TR) criteria
  3. Presence of hypertension (defined as systolic > 140 or diastolic > 90 or currently receiving antihypertensive therapy)
  4. Minimum depression severity of ≥ 15 on the Montgomery-Asberg Depression Rating Scale (MADRS)
  5. Cognitively intact or with mild cognitive deficits, with a minimum score ≥ 23 on the Montreal Cognitive Assessment (MoCA).

Exclusion Criteria:

  1. Other psychiatric Axis I disorders
  2. Acute suicidality
  3. Electroconvulsive therapy in the last 6 months
  4. Primary neurological disorder, including dementia and stroke
  5. Significant cardiovascular disease, specifically diagnosis of congestive heart failure, known bilateral renal artery stenosis, symptomatic hypotension, or critical aortic or mitral stenosis
  6. Myocardial infarction or open-heart surgery in last 6 weeks
  7. Serum creatinine ≥ 265 micromol /L
  8. Serum potassium ≥ 5.5 mmol/L
  9. MRI contraindications
  10. Known allergy to sertraline or candesartan specifically or known allergy to other SSRIs or ARBs.
  11. History of prolonged (> 3 weeks) or self-described severe discontinuation syndrome in the past after stopping an antidepressant.
  12. Current use of an angiotensin receptor blocker
  13. Current or planned psychotherapy
  14. Need for continuous oxygen use or any medical disorder where the hypercapnia challenge would be contraindicated or put the subject at increased risk. This would include acute respiratory disease, chronic angina, or other unstable cardiac conditions.
Sexes Eligible for Study: All
60 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01794455
VR5642
No
Not Provided
Not Provided
Warren Taylor, Vanderbilt University
Vanderbilt University
Not Provided
Principal Investigator: Warren D Taylor, MD, MHSc Vanderbilt University
Vanderbilt University
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP